Changes in CD4+ T-Cell Differentiation Phenotype during Structured Treatment Interruption in Patients with Chronic HIV-1 Infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 5, 2003, Pages 475-481

  Alexander, Thomas H ^a   Ortiz, Gabriel M ^b   Wellons, Melissa F ^c   Allen, Andrew ^a   Grace II, Edward J ^b   Schweighardt, Becky ^b   Brancato, Jason ^a   Sandberg, Johan K ^b   Furlan, Scott N ^b   Miralles, G Diego ^d   Nixon, Douglas F ^b   Bartlett, John A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d Trimeris Pharmaceuticals   (United States)

Author keywords

CD4; HIV 1; Structured treatment interruption; T lymphocytes

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DRUG ADMINISTRATION SCHEDULE; HIV-1; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; REFERENCE VALUES; RNA, VIRAL; VIRAL LOAD;

EID: 0345490972     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200312150-00005     Document Type: Article

References (35)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-1730.
3. Anderson KH, Mitchell JM. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med. 2000;160:3114-3120.
4. + T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
5. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent viral reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
6. Pomerantz RJ. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis. 2002;34:91-97.
7. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
8. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science. 2000;290: 1591-1593.
9. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999;104:R-13-8.
10. Ortiz GM, Wellons M, Brancato J, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA. 2001;98:13288-13293.
11. th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle. Abstract 528-M.
12. van Lunzen J, Frahm N, Schmitz J, et al. HIV-specific CTL responses do not prevent early viral rebound and immunological deterioration after STI in chronic HIV infection. Presented at: 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle. Abstract 538-M.
13. Davey RT, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999;96:15109-15114.
14. Youle M, Janossy G, Turnbull W, et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS. 2000;14:1717-1720.
15. Garcia F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001;15:F29-F40.
16. Orenstein JM, Bhat N, Yoder C, et al. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. AIDS. 2000;14:1709-1715.
17. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T-cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998;4:208-214.
18. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissue. J Clin Invest. 1999;103:1391-1398.
19. Autran B, Carcelain G, Li TS, et al. J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
20. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998; 102:79-87.
21. Hengel RL, Jones BM, Kennedy MS, et al. Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. J Immunol. 1999;163:3539-3548.
22. Hengel RL, Jones BM, Kennedy MS, et al. CD4+ T-cells programmed to traffic to lymph nodes account for increases in numbers of CD4+ T-cells up to 1 year after initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection. J Infect Dis. 2001;183: 93-97.
23. Douek DC, Betts MR, Hill BJ, et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol. 2001;167: 6663-6668.
24. Sallusto F, Lenig D, Förster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
25. Schweighardt B, Ortiz GM, Grand RM, et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002;16:2342-2344.
26. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106-111.
27. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396: 690-695.
28. Hatano H, Vogel S, Yoder C, et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS. 2000;14:1357-1363.
29. Deeks SG, Hoh R, Grant RM, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002;185:315-323.
30. Wellons MF, Ottinger JS, Weinhold KJ, et al. Immunologic profile of human immunodeficiency virus-infected patient during viral remission and relapse on antiretroviral therapy. J Infect Dis. 2001; 183:1522-1525.
31. Stoddart CA, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001;7:712-718.
32. th Conference on Retroviruses and Opportunistic Infections; 2003; Boston.
33. Dybul M, Chun T, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virulogic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A. 2001;98:15161-15166.
34. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
35. th Conference on Retroviruses and Opportunistic Infections; 2003; Boston.